Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company based in Burnaby, British Columbia, with a U.S. subsidiary in Delaware. It discovers, develops, and seeks to commercialize therapies for neurological and psychiatric disorders, with a pipeline centered on ion-channel modulators such as azetukalner.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaLate-stage investigational therapy programs centered on azetukalner.
Early-stage ion-channel programs including Kv7 and Nav modulators.
Milestone and license revenue from partnered programs and IP.
Asiakkaat
Xenon’s direct customers today are collaboration partners and licensees rather than end patients, because the company has not yet built a product-sales business. If approved, its future customers would include physicians, hospitals, payers, and patients in epilepsy, depression, bipolar depression, and pain markets. Commercial success will depend on clinical adoption, reimbursement, and the ability to reach specialty prescribers.
Biopharma partners that pay milestones, licenses, or royalties for selected programs and IP
Neurologists and psychiatrists who would prescribe approved therapies such as azetukalner
Insurers and public systems that influence coverage, access, and uptake
Patients with epilepsy, major depressive disorder, bipolar depression, or pain who would use approved drugs
Strategia
Xenon’s strategy is to build a fully integrated biopharmaceutical company around proprietary neuroscience programs, led by azetukalner. It aims to advance selected candidates through late-stage development, expand the pipeline through discovery, in-licensing, or acquisitions, and use collaborations where they improve reach or economics.
The lead asset is central to future value creation and any eventual product revenue
Future launches require sales, distribution, and market access capabilities
Additional programs reduce single-asset dependence and extend growth options
Maantiede
Xenon is headquartered in Burnaby, British Columbia and operates through a U.S. subsidiary in Delaware, reflecting a Canada-based corporate structure with U.S. capital markets access. Its business is primarily North American in development and commercialization terms, but clinical trials, manufacturing, and regulatory review can extend across the U.S., Canada, Europe, and other foreign markets. Geography matters because regulatory approvals, clinical sites, manufacturing supply chains, and future commercialization channels may differ by region.
Riskit
Xenon’s main risks come from clinical development, regulatory approval, and the difficulty of manufacturing and commercializing CNS drugs. As a development-stage biopharma company, it also depends on collaboration revenue, external financing, and third-party manufacturers, all of which can affect timing and execution.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Azetukalner and other programs are still in development, so trial outcomes may not support approval
Kohdistuu: Lead asset and pipeline value
- Regulatory approval and review riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
FDA, EMA, and other agencies can require additional data, delay filings, or reject applications
Kohdistuu: Late-stage programs and commercialization timing
- Manufacturing and supply-chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third-party manufacturers and logistics providers for clinical and future commercial supply
Kohdistuu - Commercial execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Xenon has no established sales or marketing infrastructure and may need partners or a new buildout
Kohdistuu: Future product launch economics
- Financing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business has historically funded operations through equity and collaboration receipts
Kohdistuu: R&D continuity and launch preparation
Kirjanpito
Harkinnanvaraiset erätMilestones and license payments may be recognized when performance obligations are met, creating uneven revenue
Vaikutus: Can cause large quarter-to-quarter swings in reported revenue
Clinical trial, manufacturing, and preclinical costs are expensed as incurred
Vaikutus: Directly drives operating loss and comparability across periods
Equity awards require valuation assumptions and affect G&A and R&D expense
Vaikutus: Can materially affect reported operating expenses
Future collaboration or product revenue may depend on contract terms and milestone timing
Vaikutus: Important for interpreting non-product revenue
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Xencor Inc
XNCR · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Biohaven Ltd.
BHVN · Pharmaceutical Preparations
Zenas BioPharma, Inc.
ZBIO · Pharmaceutical Preparations
Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases.
Zentalis Pharmaceuticals, Inc.
ZNTL · Pharmaceutical Preparations
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies.
Päivitetty: 24.9.2026